

GSK2141795 in patients with advanced uveal melanoma. *Journal of Clinical Oncology*. 2016;34(15_suppl):9511-9511.

49. Sorrentino G, Ruggeri N, Specchia V, et al. Metabolic control of YAP and TAZ by the mevalonate pathway. *Nat Cell Biol*. 2014;16(4):357-366.

50. Amaro AA, Gangemi R, Emionite L, et al. Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma. *Cancers (Basel)*. 2023;15(3).

51. Wu X, Li J, Zhu M, et al. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF- κ B pathways. *Mol Cancer Ther*. 2012;11(9):1905-1914.

52. Park JJ, Stewart A, Irvine M, et al. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling. *Cancer Gene Therapy*. 2022;29(10):1384-1393.

53. Cao L, Chen S, Sun R, et al. Darovasertib, a novel treatment for metastatic uveal melanoma. *Front Pharmacol*. 2023;14:1232787.

54. Chen X, Wu Q, Tan L, et al. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. *Oncogene*. 2014;33(39):4724-4734.

55. Bauer S, Larkin J, Hodi FS, et al. A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma. *Frontiers in Oncology*. 2023;12.

56. Khalili JS, Yu X, Wang J, et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. *Clin Cancer Res*. 2012;18(16):4345-4355.

57. Pereira PR, Odashiro AN, Marshall JC, et al. The role of c-kit and imatinib mesylate in uveal melanoma. *J Carcinog*. 2005;4:19.

58. Penel N, Delcambre C, Durando X, et al. O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. *Invest New Drugs*. 2008;26(6):561-565.

59. Sacco J, Nathan P, Danson S, et al. Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma. *Journal of Clinical Oncology*. 2013;31:9031-9031.

60. Mouriaux F, Serois V, Parienti JJ, et al. Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study. *Br J Cancer*. 2016;115(1):20-24.

61. Bhatia S, Moon J, Margolin KA, et al. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. *PLoS One*. 2012;7(11):e48787.

62. Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. *Genes*

Cancer. 2011;2(12):1097-1105.

63. Missotten GS, Notting IC, Schlingemann RO, et al. Vascular endothelial growth factor in eyes with uveal melanoma. *Arch Ophthalmol*. 2006;124(10):1428-1434.

64. Yang H, Jager MJ, and Grossniklaus HE. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. *Invest Ophthalmol Vis Sci*. 2010;51(6):2835-2842.

65. Tarhini AA, Frankel P, Margolin KA, et al. Aflibercept (VEGF Trap) in inoperable stage III or stage IV melanoma of cutaneous or uveal origin. *Clin Cancer Res*. 2011;17(20):6574-6581.

66. Piperno-Neumann S, Diallo A, Etienne-Grimaldi MC, et al. Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma. *Oncologist*. 2016;21(3):281-282.

67. Sharma A, Stei MM, Fröhlich H, et al. Genetic and epigenetic insights into uveal melanoma. *Clin Genet*. 2018;93(5): 952-961.

68. Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. *Cold Spring Harb Perspect Biol*. 2014;6(4):a018713.

69. Landreville S, Agapova OA, Matatall KA, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in Uveal Melanoma. *Clin Cancer Res*. 2012;18(2):408-416.

70. Dai W, Zhou J, Jin B, et al. Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma. *Sci Rep*. 2016;6:22622.

71. Jespersen H, Olofsson Bagge R, Ullenhag G, et al. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. *BMC Cancer*. 2019;19(1):415.

72. Faião-Flores F, Emmons MF, Durante MA, et al. HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. *Clin Cancer Res*. 2019;25(18):5686-5701.

73. Booth L, Roberts JL, Sander C, et al. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Ga(q) and Ga(11) and kill uveal melanoma cells. *Cancer Biol Ther* 2019;20(5):700-710.

74. Rowcroft A, Loveday BPT, Thomson BNJ, et al. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. *HPB (Oxford)*. 2020;22(4):497-505.

75. Mariani P, Piperno-Neumann S, Serois V, et al. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. *Eur J Surg Oncol*. 2009;35(11):1192-1197.

76. Mariani P, Almubarak MM, Kollen M, et al. Radiofrequency ablation and surgical management of liver metastases from uveal melanoma. *Eur J Surg Oncol*. 2016;42(5):706-712.

77. Serois V, Bouhadiba T, Dureau S, et al. Iterative treatment with surgery and radiofrequency ablation of uveal melano-

ma liver metastasis: Retrospective analysis of a series of very long-term survivors. *Eur J Surg Oncol*. 2019;45(9):1717-1722.

78. Ghanaati H, Mohammadifard M, Mohammadifard M. A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma. *J Family Med Prim Care*. 2021;10(10):3553-3560.

79. Sundram FX, Buscombe JR. Selective internal radiation therapy for liver tumours. *Clin Med (Lond)*. 2017;17(5):449-453.

80. Laface C, Laforgia M, Molinari P, et al. Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art. *Cancers (Basel)*. 2021;13(12).

81. Dewald CLA, Warnke MM, Brünig R, et al. Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience. *Cancers (Basel)*. 2021;14(1).

82. Bailey FP, Clarke K, Kalirai H, et al. Kinome-wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics. *Pigment Cell Melanoma Res*. 2018;31(2):253-266.

83. Croce M, Ferrini S, Pfeffer U, et al. Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives. *Cancers (Basel)*. 2019;11(6).

84. Béliveau A, Bérubé M, Rousseau A, et al. Expression of integrin alpha5beta1 and MMPs associated with epithelioid morphology and malignancy of uveal melanoma. *Invest Ophthalmol Vis Sci*. 2000;41(8):2363-2372.

85. Lai K, Conway RM, Crouch R, et al. Expression and distribution of MMPs and TIMPs in human uveal melanoma. *Exp Eye Res*. 2008;86(6):936-941.

86. Advani R, Flinn I, Popplewell L, et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. *N Engl J Med*. 2018;379(18):1711-1721.

87. Li YF, Dong L, Li Y, Wei WB. A Review of MicroRNA in Uveal Melanoma. *Onco Targets Ther*. 2020;13:6351-6359.

88. Li Y, Luo JT, Liu YM, et al. miRNA-145/miRNA-205 inhibits proliferation and invasion of uveal melanoma cells by targeting NPR1/CDC42. *Int J Ophthalmol*. 2020;13(5):718-724.

89. Qi Y, Cui Q, Zhang W, et al. Long Non-Coding RNA GAS5 Targeting microRNA-21 to Suppress the Invasion and Epithelial-Mesenchymal Transition of Uveal Melanoma. *Cancer Manag Res*. 2020;12:12259-12267.

90. Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. *Clin Cancer Res*. 2010;16(24): 6083-6092.

91. Bilmin K, Synoradzki KJ, Czarnecka AM, et al. New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma. *Cancers (Basel)*. 2021;14(1).

92. Kines RC, Varsavsky I, Choudhary S, et al. An Infrared Dye-Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma. *Mol Cancer Ther*. 2018;17(2):565-574.

Onkologie
www.onkologiecs.cz

